Company intelligence / Profile preview

Hunan Siqi Biopharmaceutical

Changsha, Hunan, China

Ownership: Private
Development stage: Other

Overview

Hunan Siqi Biopharmaceutical is a clinical-stage biotechnology company based in Changsha, China, focused on the development of mRNA therapeutics and vaccines. The company utilizes a proprietary mRNA-LNP delivery platform to create treatments for infectious diseases and various cancers. Its lead candidate, SQZ-7, is an mRNA vaccine targeting COVID-19 that has entered clinical trials. Beyond infectious diseases, Siqi Bio is actively developing personalized neoantigen-based cancer vaccines and other prophylactic vaccines. The firm maintains integrated capabilities spanning from sequence design and optimization to large-scale GMP manufacturing.

Therapeutic areas: OncologyInfectious Diseases
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyVaccine
Industry: Biotech

Beyond the preview

Go deeper on Hunan Siqi Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hunan Siqi Biopharmaceutical.

Explore the full profile